Abacavir tolerability profile reassured

Studies presented at the 3rd International AIDS Society (IAS) Conference [Rio De Janeiro, Brazil; July 2005] showed that there were no differences in the incidences of hypersensitivity reactions when abacavir is administered once or twice daily and as a single agent or combination product. In another study, patients with hepatitis co-infections did not have any increases in the incidence and type of adverse events with abacavir, compared with patients without co-infection. A fourth study showed that abacavir-containing regimens were superior to stavudine-containing regimens with respect to effects on insulin resistance, glycaemic control and levels of cytokines.